Skip to main content

Search
Profile

Douglas S. Hawkins, MD

|
Douglas S. Hawkins, MD

Hematology-Oncology

On staff since February 1996

Children's Title: Associate Division Chief, Hematology/Oncology

Academic Title: Professor of Pediatrics, UW School of Medicine

Research Center: Center for Clinical and Translational Research

"I feel exceptionally fortunate to work with some of the smartest people I know. Every day brings new opportunities to learn from my colleagues, patients and families. By the nature of our work in Hematology/Oncology, there is never a question about the importance of what we do every day. I am continually impressed that we have the opportunity to change the lives of children and young adults for the better, both with good clinical care and by leading clinical and translational research efforts. My hope is that the clinical research we do today will lead to more effective treatments with fewer side effects for children and young adults in the future."

Recommendations

RahilKent, WA10.19.12
Dr. Hawkins is a professional, kind and caring doctor with a large expertise in treating childhood cancer. Upon our orientation at Children's, he was the key person that explained the medicines, treatment plan, schedule and expectations. He explained differences in treatment plans in Europe and North America. He presented our scans, biopsy and test results making sure that we understood everything. He has done a good job and our son is now cured of cancer. Thank you Dr. Hawkins and the expert staff at Seattle Children's!
HeatherSnoqualmie, WA09.25.12
Dr. Hawkins and his incredible team saved out daughters life. Dr. Hawkins had the insight to look past the original diagnosis given to our daughter. She was diagnosed with TEC at 15 months with a HCT of 7. This was not life sustaining. He and his team consulted, worked, planned and communitcated with each other and our family to come up with the best course of treatment. I cant thank Dr. Hawkins and Seattle Children's enough. They preform miracles everyday!
janicewenatchee, wa.02.13.12
Dr. Hawkins works around the clock to give our children the best care. I am happy to say my son is a bone cancer survivor. I appreciated how Dr. Hawkins worked to make sure the side affects from the chemo where addressed as well as its progress. Thank you so much, Janice B.
elcekent,washinton09.28.11
Dr. Hawkins saved my daughters life,who was diagnosed with stage 4 alveolar rhabdomyosarcoma last year.My daughter is cancer free for almost three months now because of Dr. Hawkins and his team.God bless them.God is Good.
Beckyseattle ,wa06.16.11
I was a distraught parent when my daughter was diagnosed at 15 with Hodgkin's lymphoma. he spent the time to make me feel at ease and encouraged me to participate in her care . i didn't have a clue what i should do . he made me feel comfortable to ask a lot of questions, and he answered with reassurance and calmness . He worked closely with me as a parent as well as his colleagues to give her the best care she could get. he responded as quickly as possible to all of my phone calls. He is a very humble man for all of his qualifications . there are a lot of people who look up to him , if he only knew how many .... many thanks!! we pray for his continued success!!
LynoraKetchikan, Alaska04.14.11
Five years ago, my 8 1/2 year old son was diagnosed with Hodgkin's Lymphoma. I remember Dr Hawkins looking me right in the eye and saying, "This cancer is very, very, VERY curable." I clung to his words, and today we are celebrating my son's 14th birthday. Thank you Dr. Hawkins, and Children's, for assisting God in our son's healing!
KathleenSeattle, WA03.30.11
If you are seeing Dr. Hawkins, you've likely heard the worst thing you will ever hear: your child has cancer. If that's the case, thank God you're seeing Dr. Hawkins! My son nearly died before he was diagnosed in 1997 at age 2 with Burkitt's Lymphoma. We were so grateful to have Dr. Hawkins on his team. He's honest, clear, compassionate and simply the most knowledgeable physician treating kids today. My son is 16 now, rowing crew and making the honor roll!
camilleseattle washington02.17.11
Dr. Hawkins is my personal Hero! I was two weeks short of dying when he took over. I had stage 4 hodgkins lymphoma I was 15 yrs old. I am now 20 and I have a beautiful son and have been in remisson for 5 yrs now. Thank you Dr. Hawkins!
LynoraKetchikan, Alaska04.14.11
Five years ago, my 8 1/2 year old son was diagnosed with Hodgkin's Lymphoma. I remember Dr Hawkins looking me right in the eye and saying, "This cancer is very, very, VERY curable." I clung to his words, and today we are celebrating my son's 14th birthday. Thank you Dr. Hawkins, and Children's, for assisting God in our son's healing!
TammyMaple Valley, WA12.10.10
Dr. Doug Hawkins and Dr. Lawrence Cooper diagnosed our son Eric as a Lg Cell Lymphoma patient in early 1997 when he was 10. Eric recently had his 24th Birthday, THANKS TO THEIR KNOWLEDGE AND CARE. He is a SURVIVOR!! Thank you to them and all the wonderful nurses that made that hard time bearable. Sincerely, Eric's Mom & Dad
Recommend Dr. Douglas Hawkins

Overview

Board Certification(s)
Pediatric Hematology-Oncology
Medical/Professional School
Harvard Medical School, Boston
Residency
Pediatrics, University of Washington, Seattle
Clinical Interests

Sarcomas, New therapy

Research Description

My clinical research is particularly focused in the treatment of pediatric sarcomas. I am the Children's Oncology Group (COG) chair of the Soft Tissue Sarcoma Committee, which designs and conducts all national studies in pediatric soft tissue sarcomas, including rhabdomyosarcoma. I am the COG chair of two clinical trials, one for Ewing sarcoma and another for rhabdomyosarcoma, and the vice chair of three other COG clinical trials. I am working collaboratively on a pharmacogenomic study investigating cyclophospharmide metabolism and toxicity, both locally and as part of two COG studies, and on the use of FDG PET to assess response and guide treatment in pediatric sarcomas.

Research Focus Area

Cancer

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
U.S. News Top DoctorU.S. News and World Report 2012
Seattle Magazine Top Doctor - 2012Seattle Magazine Top Doctor - 2012Seattle Magazine 2012
Seattle Magazine Top Doctor - 2011Seattle Magazine Top Doctor - 2011Seattle Magazine 2011

Publications

Early treatment failure in intermediate-risk rhabdomyosarcoma: results from IRS-IV and D9803--a report from the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Sep 20: 4228-32
Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Sep 13
Fusion-Negative Alveolar Rhabdomyosarcoma: Modification of Risk Stratification Is Premature.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2010 Aug 9
Local Therapy for Rhabdomyosarcoma of the Hands and Feet: Is Amputation Necessary? A Report from the Children's Oncology Group.
International journal of radiation oncology, biology, physics , 2010 Jun 18
Regional Nodal Involvement and Patterns of Spread Along In-transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group.
International journal of radiation oncology, biology, physics , 2010 Jun 11
No evidence of a trial effect in newly diagnosed pediatric acute lymphoblastic leukemia.
Archives of pediatrics & adolescent medicine , 2010 Mar: 214-7
Malignant progression in two children with multiple osteochondromas.
Sarcoma , 2010: 417105
Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2009 Dec 1: 7361-7
Pegfilgrastim for prevention of chemotherapy-associated neutropenia in pediatric patients with solid tumors.
Pediatric blood & cancer , 2009 Sep: 375-8
Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2009 Aug 1: 3705-11
[F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
Cancer , 2009 Aug 1: 3519-25
COX-2 expression correlates with survival in patients with osteosarcoma lung metastases.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2008 Jul: 507-12
Two boys with fragile x syndrome and hepatic tumors.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2008 Mar: 239-41
Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia.
Pediatric blood & cancer , 2008 Jan: 189
Delayed radiotherapy following dose intensive chemotherapy for parameningeal rhabdomyosarcoma (PM-RMS) of childhood.
European journal of cancer (Oxford, England : 1990) , 2007 Apr: 1045-50
Pediatric intradural extramedullary synovial sarcoma: case report.
Neurosurgery , 2006 Dec: E1339; discussion E1339
Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Pediatric blood & cancer , 2006 Nov: 790-4
Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Cancer , 2006 Sep 15: 1400-6
Survival of tumor megaprostheses replacements about the knee.
Clinical orthopaedics and related research , 2006 Sep: 39-45
[18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Dec 1: 8828-34
Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2005 Nov 15: 8089-96
Fas expression in lung metastasis from osteosarcoma patients.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2005 Nov: 611-5
Survival after recurrence of Ewing's sarcoma family of tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2005 Jul 1: 4354-62
Metastatic malignant melanoma presenting as pancytopenia in a three-year-old boy.
Pediatric blood & cancer , 2005 Jul: 60-3
Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.
Cancer , 2005 Jan 15: 339-48
Transatlantic collaboration in pediatric oncology: now is the time.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2004 Dec: 783-4
Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
Pediatric blood & cancer , 2004 Oct: 571-9
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research , 2004 Aug 15: 5335-41
Influence of age upon Ifosfamide-induced nephrotoxicity.
Pediatric blood & cancer , 2004 May: 427-32
Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
Cancer , 2004 Mar 15: 1268-75
Evaluation of early marrow response in childhood aneuploid acute lymphoblastic leukemia: flow cytometric DNA analysis versus standard morphology.
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society , 2004 Jan-Feb: 39-47
Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy.
Cancer , 2003 Dec 1: 2447-56
Intensive induction chemotherapy and delayed irradiation in the management of parameningeal rhabdomyosarcoma.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2003 Oct: 774-9
Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2003 Apr: 286-91
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Cancer , 2002 Sep 15: 1354-65
Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology , 2002 Aug-Sep: 440-6
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
Cancer , 2002 Jun 15: 3277-84

Presentations

Presentations TitleEventLocationDate
Rhabdomyosarcoma: Biology and clinical trialsTexas Children’s Cancer CenterHouston, TXNov. 12, 2009
What children have taught me about rhabdomyosarcomaThird Annual James S. Miser Lectureship, City of HopeDuarte, CAOct. 9, 2009
Meet the Professor: Pediatric SarcomasAmerican Society of Clinical OncologyOrlando, FLMay 31, 2009

Research Funding

Grant TitleGrantorAmountAward Date
Children’s Oncology Group trial AEWS0531NIH $11,956.00March 1, 2009
Children’s Oncology Group trial AEWS0331NIH $11,956.00March 1, 2009
Children’s Oncology Group Soft Tissue Sarcoma Committee ChairNIH $23.913.00March 1, 2009
Children’s Oncology Group- cooperative group trial, Institutional Principal NIH $57,390.00March 1, 2009
Children’s Oncology Group trial AEWS0531NIH $13,995.00March 1, 2008
Children’s Oncology Group trial AEWS0331NIH $11,663.00March 1, 2008
Children’s Oncology Group- cooperative group trialNIH $55,980 .00March 1, 2008
Acute Lymphoblastic Leukemia ResearchOrrico Foundation $333,109.00Feb. 1, 1997
Pilot Study of VACIME with Peripheral Blood Progenitor Cells and Neupogen for Patients with Metastatic Sarcoma at Diagnosis, Phase I Study of Thiotepa in Combination with Fixed Doses of Carboplatin and Topotecan for Children with Recurrent or Refractory Solid Tumorsk 166Ho-DOTMP as Targeted Radiotherapy for Recurrent or Refractory Ewing’s Sarcoma , Establishing Xenografts from Primary Pediatric Bone SarcomasGilbertson Foundation $158,150.00Sept. 1, 1996

Primary Office

Seattle Children's
MB.8.501 - Hematology-Oncology
4800 Sand Point Way NE
Seattle, WA 98105
206-987-2106

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options